Get the up-to-date Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon 2024 now

Get Form
Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon Preview on Page 1

Here's how it works

01. Edit your form online
01. Edit your form online
Type text, add images, blackout confidential details, add comments, highlights and more.
02. Sign it in a few clicks
02. Sign it in a few clicks
Draw your signature, type it, upload its image, or use your mobile device as a signature pad.
03. Share your form with others
03. Share your form with others
Send it via email, link, or fax. You can also download it, export it or print it out.

The easiest way to edit Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon in PDF format online

Form edit decoration
9.5
Ease of Setup
DocHub User Ratings on G2
9.0
Ease of Use
DocHub User Ratings on G2

Adjusting paperwork with our extensive and user-friendly PDF editor is simple. Follow the instructions below to fill out Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon online easily and quickly:

  1. Sign in to your account. Sign up with your credentials or register a free account to test the service before upgrading the subscription.
  2. Import a form. Drag and drop the file from your device or add it from other services, like Google Drive, OneDrive, Dropbox, or an external link.
  3. Edit Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon. Easily add and highlight text, insert images, checkmarks, and icons, drop new fillable fields, and rearrange or remove pages from your document.
  4. Get the Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon completed. Download your updated document, export it to the cloud, print it from the editor, or share it with others via a Shareable link or as an email attachment.

Take advantage of DocHub, the most straightforward editor to quickly manage your documentation online!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.
Contact us
Avoid decongestants and medications that contain stimulants such pseudoephedrine or ephedrine, which are found in cold, flu, sinus, allergy and headache medications. Those medications cause blood vessels to constrict, which can worsen PH and increase blood pressure and heart rate.
There is no cure for PAH, but several medications like endothelin receptor antagonists (ERAs), prostacyclin analogues (PCAs) and riociguat, a soluable guanylate cyclase stimulator, are available to help slow the progression of changes in the pulmonary arteries and help reduce symptoms.
Tyvaso DPI may improve patients ability to exercise, reduce strain on the heart and lessen disease progression. The Food and Drug Administration approved Tyvaso DPI to treat PAH and interstitial lung disease in May 2022.
Warfarin (Coumadin) is prescribed for most patients with pulmonary arterial hypertension. There is some data from research studies that this medication may improve survival as patients with PAH are at increased risk to develop blood clots.
Examples of vasodilators to treat pulmonary hypertension include epoprostenol (Flolan, Veletr), treprostinil (Remodulin, Tyvaso, others), Iloprost (Ventavis) and selexipag (Uptravi). Soluble guanylate cyclase (sGC) stimulators. This type of medicine relaxes the pulmonary arteries and lowers pressure in the lungs.
be ready to get more

Complete this form in 5 minutes or less

Get form

People also ask

While existing treatments are designed to help manage the symptoms of PH, sotatercept is the first to target the root cause of the disease. Neil Hamilton, Consultant Pharmacist in PH, told us: Sotatercept is an exciting new treatment which works in a different way to any of the current medicines we can prescribe.
The currently FDA approved inhaled PH therapies include inhaled iloprost for group 1 pulmonary arterial hypertension (PAH), inhaled treprostinil solution and treprostinil dry powder inhaler for both group 1 PAH and group 3 PH associated with interstitial lung disease (PH-ILD).
Bosentan (Tracleer) This is the first oral medication specifically approved for the treatment of pulmonary hypertension. It is approved for patients with advanced disease due to PAH or docHub tissue disease associated pulmonary hypertension.

Related links